drugset / Trial / NCT01777282

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

NCT01777282

Phase 3 Completed 374 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.

Timeline

Start
2013-02-23
Primary completion
2015-01-27
Completion
2015-01-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator albiglutide Peptide 30 mg Subcutaneous
Comparator albiglutide Peptide 50 mg Subcutaneous